<DOC>
	<DOCNO>NCT01632202</DOCNO>
	<brief_summary>Seprafilm FDA-approved temporary bioresorbable barrier physically separate oppose tissue surface . The physical presence membrane separate adhesiogenic tissue normal tissue repair process take place . When used abdominopelvic cavity , show reduce incidence adhesion . The intrauterine cavity potential space wall uterus collapse upon normal state . It demonstrate trauma remove submucosal fibroid electrocautery expose uterus great potential intrauterine adhesion since raw char surface directly oppose opposite endometrial surface . Previous study show placement hyaluronic acid intrauterine cavity myomectomy safe , also decrease incidence intrauterine adhesion . The investigator hypothesize place slurry Seprafilm intrauterine cavity create temporary physical barrier wall uterus , able prevent iatrogenic intrauterine adhesion . Given approximately 24 48 hour placement , membrane becomes hydrate gel slowly resorb within one week , investigator anticipate patient minimal discomfort ; since physical device leave endometrial cavity , uterus contract normal postoperative state .</brief_summary>
	<brief_title>Seprafilm Slurry Prevention Uterine Scarring Patients Undergoing Hysteroscopic Myomectomy</brief_title>
	<detailed_description>The investigator conduct randomize controlled trial ( RCT ) involve patient NewYork Presbyterian Hospital-Columbia University Medical Center Weill Medical College Cornell University . The investigator enroll 328 pre- menopausal patient ( &gt; 18years ) document submucosal myoma undergo hysteroscopic myomectomy monopolar resection study . The investigator anticipate approximately 30 % patient undergoing myomectomy form intrauterine adhesion administration Seprafilm slurry reduce incidence approximately 15 % . Patients query post-operative day 1 , 7 , 30 pain/discomfort degree intrauterine adhesion assess patient 's second menses ( 75-90 day post procedure ) .</detailed_description>
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Reproductive age woman : Age 1848 year old Nonpregnant Otherwise healthy Regular menstrual cycle Documented submucosal myoma ( one ) Undergoing hysteroscopic myomectomy Patients must sign informed consent . Age &lt; 18 menopause Undergoing second uterine surgical procedure Other significant uterine pathology ( include limited adhesion , septae , cancerous lesion ) Hysteroscopic evidence synechiae time procedure Surgeries complicate excessive bleeding ; define estimate blood loss &gt; 100cc give presence excessive bleeding may predispose patient formation intrauterine adhesion Surgeries complicate uterine perforation Surgeries complicate postoperative intrauterine infection give infection may predispose patient formation intrauterine adhesion ( If patient receive Seprafilm Slurry , continue follow safety monitoring )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>submucosal myoma</keyword>
	<keyword>intrauterine adhesion</keyword>
	<keyword>hysteroscopic myomectomy</keyword>
	<keyword>seprafilm</keyword>
</DOC>